Trials / Unknown
UnknownNCT02382198
Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease
A Randomized, Placebo-controlled, 2-arm Parallel-group Superiority Phase II Study of GLYCOpyrrolate for Moderate-to-severe Sialorrhea in PARkinson's Disease
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- Ottawa Hospital Research Institute · Academic / Other
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
Sialorrhea is a frequently occurring problem with detrimental effect on quality of life in 25% of PD patients. Currently, there is no intervention approved for sialorrhea in Parkinsons and evidence is only available for a 30-day effect or less. We hypothesize that glycopyrrolate will have a lasting effect in the reduction of sialorrhea in PD patients.
Detailed description
To assses if Glycopyrrolate has a long lasting effect on sialorrhea for patients with Parkinsons.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glycopyrrolate | Drug to reduce drooling in patients with Parkinson's Decease. |
| DRUG | Placebo |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2018-10-01
- Completion
- 2018-12-01
- First posted
- 2015-03-06
- Last updated
- 2018-04-17
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02382198. Inclusion in this directory is not an endorsement.